ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Thomas Ernst(Jena University Hospital), M. C. Muller(Heidelberg University)
Cited by 50
Related Papers
PD-1 Blockade in Anaplastic Thyroid Carcinoma
|Journal of Clinical Oncology|2020|349
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
|Leukemia|2015|274